ADA and myeloid sarcoma: To support clinical use of alemtuzumab in our clinical practice—as it is a valuable treatment for many people with MS, and the possibility of third and fourth courses of treatment were available (5, 48)—we developed a novel assay to detect ADA against alemtuzumab, using a synthetic recombinant construct Alem GloBody (64).